|
BRIEF-GSK asthma drug meets main goal in safety study
Reuters Oct 27 Glaxosmithkline Plc. * GSK's Advair Diskus achieves primary endpoint in LABA safety study of patients with asthma. * Results from study showed FSC twice-daily demonstrated non-inferiority compared to corresponding doses of FP twice-daily. |
View full post on asthma – Google News